Identification and targeting of selective vulnerability rendered by tamoxifen resistance

BACKGROUND: The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main hurdle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Singh, Madhurendra, Zhou, Xiaolei, Chen, Xinsong, Santos, Gema Sanz, Peuget, Sylvain, Cheng, Qing, Rihani, Ali, Arnér, Elias S. J., Hartman, Johan, Selivanova, Galina
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7388523/
https://ncbi.nlm.nih.gov/pubmed/32727562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01315-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados